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 Fig. 1. (Left) Short-axis image and the corresponding RR2 maps: (middle) off and (right) on chelation for 
one week. Color maps are displayed with color scale ranging from 0-40 (in units of s-1). Arrows indicate the 
septal wall. 
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Introduction: For patients with transfusional iron overload, improved non-invasive methods for monitoring iron-chelating therapy are needed. As 
transfusional iron overload develops, almost all the excess iron is sequestered intracellularly as ferritin iron, a dispersed, soluble fraction that can be 
rapidly mobilized, and hemosiderin iron, an aggregated, insoluble fraction that serves as a long-term reserve. Recent investigations provide compelling 
evidence that the intracellular ferritin iron concentration is in equilibrium with the low molecular weight cytosolic iron pool [1] accessed by iron chelators. 
Consequently, measurements of tissue ferritin iron concentrations could provide an indicator of the effectiveness of iron-chelating agents. MRI offers a 
means to non-invasively assess tissue iron concentrations in both liver and heart by exploiting the paramagnetic effects of iron on the relaxation rates of 
solvent protons, such as R1, R2, or R2*. At present, the most widely used method is breath-hold R2* imaging [2], which has been shown to detect 
myocardial [3] and hepatic [4] iron deposition. R2* is predominantly influenced by hemosiderin iron and changes very slowly even with intensive iron-
chelating therapy [5]. We propose a breath-hold fast spin echo (FSE)[6] sequence for accurate imaging of myocardial and hepatic R2 [7] that permits 
calculation of RR2, a “reduced R2” that provides a measure of ferritin iron that is independent of hemosiderin iron [8]. The purpose of our study was to 
compare the sensitivity of RR2 (as a measure of ferritin iron) with that of conventional relaxation times, R2 and R2*(as predominantly reflecting 
hemosiderin iron) in detecting changes in myocardial iron produced by one week of therapy with the oral iron-chelating agent, deferasirox. 
 
Methods: The breath-hold R2* and FSE sequences were implemented on a 1.5T whole-body MR scanner (Avanto, Siemens) equipped with a 32-
channel cardiac array coil. For pulse sequence details, please see references [2, 7], respectively. Relevant imaging parameters for the FSE sequence 
include: FOV = 340 x 276 mm, matrix = 128 x 78, slice thickness = 10 mm, GRAPPA acceleration factor = 1.8, BW = 500 Hz/pixel, ESP = 5.6 ms, echo-
train duration ~ 120 ms, double-inversion black-blood preparation pulse, and breath-hold duration of 20-22 s. Image acquisition was repeated for two 
additionally different inter-echo spacing (ESP) of 7 (BW = 295 Hz/pixel; number of images =8) and 10 ms (BW = 155 Hz/pixel; number of images =6), 
respectively, in order to quantify non-monoexponential T2 decay in the presence of soluble (ferritin) and particulate (hemosiderin) iron [8]. Relevant 
imaging parameters for the R2* sequence include: FOV = 340 x 276 mm, matrix = 128 x 78, slice thickness =10 mm, GRAPPA acceleration factor = 1.8, 
BW = 1500 Hz/pixel, ESP = 0.97 ms, number of images = 10, black-blood preparation pulse, flip angle = 15°, and breath-hold duration = 9-10 s. Five 
adult patients (4 males; 1 female) with thalassemia major were imaged in a mid-ventricular short-axis view of the heart, first after being off iron-chelating 
therapy for one week, and second after resuming iron-chelating therapy (deferasirox, 20 to 30 mg/kg daily) for one week. The region-of-interest (ROI) 
was manually drawn to segment the septal wall, as previously described [3]. R2* was calculated by performing monoexponetial fitting of its data set, and 
R2 was calculated by performing monoexpoential fitting of the shorted ESP FSE data set. The reduced R2 (RR2) was calculated by non-linear least 
square fitting of the three sets of non-monoexponential relaxation curves with different ESPs [9]. RR2 has been shown to be able to detect ferritin levels 
independently of hemosiderin levels [8]. The R2*, R2, and RR2 values were compared between off and on chelation states.    
 
Results: Figure 1 shows a representative short-axis image (Subject 5) and the corresponding myocardial RR2 maps after one week off iron-chelating 
therapy (middle panel) and one week after resuming iron chelation therapy (right panel). Table 1 shows the values for myocardial R2*, R2, and RR2 after 
one week off iron-chelating therapy (chelation off) and one week after resuming iron chelation therapy (chelation on). The effect of one week of iron-
chelating therapy was reflected by a decrease of RR2 from a mean of 27.4 to 24.8 s-1 (P = 0.006, using a paired t-test). No significant differences were 
found in myocardial R2 or R2*. 
 
Discussion: These results provide evidence that a single week of deferasirox iron-chelating therapy produces a decrement in myocardial iron 
detectable as a significant decrease in RR2. This observation is consistent with the hypothesis that RR2 measures myocardial ferritin iron which is in 
equilibrium with the low molecular weight cytosolic iron pool accessed by iron chelators. Conventional relaxation times, R2 and R2*, predominantly 
influenced by hemosiderin iron, showed no significant change. Measurement of myocardial RR2 may provide a new means of rapidly evaluating the 
effects of iron chelators on heart iron. Future work will thoroughly validate the RR2 imaging method for monitoring iron-chelation therapy for both heart 
and liver iron.  
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 R2* (s-1) R2 (s-1) RR2 (s-1) 
Subject Chelation Off Chelation On Chelation Off Chelation On Chelation Off Chelation On 
1 74.89 94.09 34.47 32.08 33.44 29.75 
2 121.98 129.92 32.72 33.85 28.90 27.87 
3 81.29 80.40 33.37 30.64 28.94 26.92 
4 50.84 42.77 24.63 23.15 23.82 20.52 
5 35.49 48.26 23.75 20.79 21.87 19.14 
 
Table 1. R2*, R2, and RR2 values of all five patients: off and on chelation therapy for one week. Only the RR2 (p < 0.006) 
was significantly different between the two chelation states.   
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